黏膜训练免疫疫苗MV130预防慢阻肺急性加重:随机3期试验
这项3期多中心双盲安慰剂对照随机试验纳入198例频繁急性加重的COPD患者,1:1接受MV130(300 FTU)或安慰剂每日治疗12个月,随访至18个月。结果显示MV130降低中重度急性加重率(2.68降至1.87事件/患者年,p<0.001),安全性可接受。
要点
- MV130可降低频繁加重COPD患者的中重度急性加重率。
- 18个月内中位加重次数安慰剂3.0次,MV130组2.0次。
- 不良事件发生率两组相似,严重不良事件未报告。
核心结论
- MV130可减少中重度COPD急性加重,提示其可作为辅助预防治疗。
研究设计与样本
- 3期多中心双盲安慰剂对照随机试验,纳入西班牙7家医院198例患者,1:1分配至MV130或安慰剂。
- 纳入标准:前一年≥3次中度急性加重,或≥2次且至少1次需住院。
- 治疗12个月,随访6个月,主要终点为18个月内急性加重次数,在ITT和PP人群中评估。
主要发现
- ITT人群中位急性加重次数:安慰剂3.0次(IQR 1.0-5.0),MV130组2.0次(IQR 1.0-3.0),p=0.001。
- MV130将急性加重率从2.68降至1.87事件/患者年(95%CI 0.44-1.18;p<0.001)。
- 103例参与者报告229例不良事件(52%),安慰剂组113例(48.5%),MV130组116例(55.7%)。
- 两例不良事件(安慰剂组荨麻疹、MV130组瘙痒)为非严重且可能与研究药物相关。
临床怎么用
- 对于频繁中重度急性加重的COPD患者,在维持治疗基础上可考虑MV130作为辅助预防措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Respiratory infections are the primary trigger of acute exacerbations in COPD, yet preventive strategies remain limited. This study aims to evaluate the efficacy and safety of MV130, a sublingual mucosal vaccine, in preventing COPD exacerbations alongside maintenance therapy. METHODS: A phase 3, multicentre, double-blind, placebo-controlled, randomised clinical trial included 198 subjects across seven hospitals in Spain, with 1:1 allocation to MV130 or placebo. Eligible patients had ≥3 moderate COPD exacerbations or≥2 with at least one requiring hospitalisation in the previous year. Patients received MV130 (300 FTU) or placebo daily for 12 months. The primary outcome, assessed in both intention-to-treat (ITT) and per-protocol (PP) populations, was the number of exacerbations over 18 months (12 months of treatment +6 months follow-up). Secondary exploratory endpoints related to healthcare resource utilisation and medication use were also evaluated in the ITT population. Safety was also assessed in the ITT population. (ClinicalTrials.gov: NCT01842360; EudraCT: 2012-003253-28). RESULTS: Between May 2013 and January 2018, 198 eligible participants (154 men, 44 women; 97 MV130, 101 placebo) were enrolled. Baseline COPD medication use was well balanced between the treatment groups. Median number of acute exacerbations in the ITT set was 3.0 [interquartile range, IQR, 1.0-5.0] for placebo versus 2.0 [IQR, 1.0-3.0] for MV130 (p=0.001). MV130 reduced exacerbation rate from 2.68 to 1.87 events per patient-year (95% CI 0.44-1.18; p<0.001). There were 229 adverse events (AEs) reported in 103 participants (52%), 113 (48.5%) in the placebo group and 116 (55.7%) in the MV130 group. Two AEs, urticaria (placebo) and pruritus (MV130), were non-serious and assessed as possibly related to the study medication. CONCLUSION: MV130 reduces moderate and severe COPD exacerbations, suggesting its potential role as an adjunct preventive therapy.
引用
- Maestu, Rubio, Benedetti, et al. Prevention of COPD exacerbations with a mucosal trained immunity-based vaccine (MV130): a randomised phase 3 trial. Eur Respir J. 2026. PMID: 42492956. doi:10.1183/13993003.00027-2026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。